| | Female | Male | P value |
| | Diagnosis, number (%) | | | | | All MPN | 164 | 106 | 0.001 | | ET | 43 (26) | 18 (17) | | | PV | 104 (64) | 57 (54) | | | MF | 17 (10) | 31 (29) | |
| | Age at diagnosis, median (IQR) | | | | | All MPN | 50 (37–61) | 56 (48–67) | 0.001 | | ET | 50 (36–59) | 48 (31–60) | | | PV | 48 (34–61) | 56 (50–66) | | | MF | 58 (51–63) | 61 (51–67) | |
| | Disease duration, median (IQR) | | | | | All MPN | 5 (3–11) | 5 (1–9) | 0.04 | | ET | 4 (2–10) | 3 (1–9) | | | PV | 6 (3–12) | 4 (1–8) | | | MF | 6 (3–12) | 6 (2–11) | |
| | Hypertension, number (%) | 2 missing | | | | All MPN | 53 (33%) | 44 (42%) | 0.15 | | ET | 13 | 4 | | | PV | 35 | 29 | | | MF | 5 | 11 | |
| | Diabetes Mellitus, number (%) | | 1 missing | | | All MPN | 7 (4%) | 8 (8%) | 0.28 | | ET | 0 | 0 | | | PV | 5 | 6 | | | MF | 2 | 2 | |
| | Dyslipidemia, number (%) | | | | | All MPN | 15 (9) | 26 (25) | 0.001 | | ET | 2 | 3 | | | PV | 12 | 15 | | | MF | 1 | 8 | |
| | Smoking history, number (%) | | | | | All MPN | 35 (22) | 40 (39) | 0.005 | | ET | 12 | 4 | | | PV | 17 | 25 | | | MF | 6 | 11 | |
| | Median white blood cell count, × 109/L (IQR) | | | | | All MPN | 9.5 (7.3, 14.8) | 13.2 (8.3, 21.4) | 0.02 | | ET | 8 (6.8, 9) | 8.7 (6–10.8) | | | PV | 11.1 (7.5,18.4) | 13.9 (9.6, 20) | | | MF | 25 (6.9, 49) | 15.9 (7.9, 26.6) | |
| | Median hemoglobin, g/dL; (IQR) | | | | | All MPN | 12.9 (11.6, 14) | 13.2 (11.4, 14.4) | 0.73 | | ET | 13.7 (12.7, 14.2) | 14.7 (13.2–15.1) | | | PV | 12.8 (11.6, 13.8) | 13.6 (12.6–14.4) | | | MF | 10.6 (9.9, 12.5) | 10 (9, 11.8) | |
| | Median Platelet count, × 109/L (IQR) | | | | | All MPN | 527 (333, 678) | 450 (246–673) | 0.09 | | ET | 568 (499–782) | 476 (412–654) | | | PV | 526 (340–667) | 502 (300–700) | | | MF | 214 (133–330) | 272 (166, 477) | |
| | JAK2 V617F allele burden, median (IQR) | | | | | All MPN | 53 (42–69) | 63 (46–83) | 0.05 | | ET | 34 (22–44) | 44 (34–48) | | | PV | 64 (50–71) | 71 (55–88) | | | MF | 82 (55–100) | 57 (48–77) | |
| | JAK2 genotype | | | 0.1 | | Heterozygous | 86 (53%) | 45 (42%) | | | Homozygous | 77 (47%) | 61 (58%) | |
| | Anti-platelet Use, number (%) | | | | | All MPN | 81 (59) | 69 (69) | 0.12 | | ET | 26 | 11 | | | PV | 50 | 41 | | | MF | 5 | 17 | |
| | Warfarin Use, number (%) | | | | | All MPN | 17 (10%) | 7 (7%) | 0.28 | | ET | 4 | 3 | | | PV | 13 | 4 | | | MF | 0 | 0 | |
| | Hydroxyurea Use, number (%) | | | | | All MPN | 48 (30%) | 28 (27%) | 0.58 | | ET | 11 | 3 | | | PV | 33 | 17 | | | MF | 4 | 8 | |
| | Interferon Use, number (%) | | | | | All MPN | 5 (3%) | 3 (3%) | 0.99 | | ET | 0 | 1 | | | PV | 4 | 0 | | | MF | 1 | 2 | |
| | Anagrelide Use, number (%) | | | | | All MPN | 11 (7%) | 4 (4%) | 0.42 | | ET | 4 | 1 | | | PV | 6 | 1 | | | MF | 1 | 2 | |
|
|
